A Phase I clinical trial of lodenafil carbonate, a new phosphodiesterase Type 5 (PDE5) inhibitor, in healthy male volunteers

Lodenafil carbonate is a new phosphodiesterase Type 5 (PDE5) inhibitor used in treatment of erectile dysfunction. Objective: The present study was conducted to evaluate the safety, tolerability, and pharmacokinetics of lodenafil carbonate after administering ascending (1 - 100 mg) single oral doses to healthy male volunteers (n = 33). Methods: The study was an open-label, dose-escalation, Phase I clinical trial involving the administration of single oral doses of lodenafil carbonate. Lodenafil carbonate was administered sequentially, escalating in single doses of 1 mg - 100 mg with a washout period of at least 1 week between each dose. The progression to the next dose was allowed after clinical and laboratory exams, Ambulatory Monitoring of Arterial Pressure (AMAP) without relevant clinical modifications and adverse events without clinical relevancy. Blood samples were collected at pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 14, 16, 20 and 24 h post-dosing. Plasma samples for measurement of lodenafil carbonate and lodenafil were analyzed by liquid chromatography coupled to tandem mass spectrometry. Results: No serious adverse events were observed, and none of the subjects discontinued the study due to intolerance. The AMAP measurements, clinical and laboratory exams and ECG revealed no significant changes even at higher doses. Lodenafil carbonate was not detected in any samples, indicating that it acts as a prodrug. The mean lodenafil pharmacokinetic parameters for t(max) and t(1/2) were 1.6 (+/- 0.4) h and 3.3 (+/- 1.1) h, respectively. This study demonstrated that lodenafil carbonate was well tolerated and showed a good safety profile in healthy male volunteers.

Exercise training improves relaxation response and SOD-1 expression in aortic and mesenteric rings from high caloric diet-fed rats

Abstract Background Obesity has been associated with a variety of disease such as type II diabetes mellitus, arterial hypertension and atherosclerosis. Evidences have shown that exercise training promotes beneficial effects on these disorders, but the underlying mechanisms are not fully understood. The aim of this study was to investigate whether physical preconditioning prevents the deleterious effect of high caloric diet in vascular reactivity of rat aortic and mesenteric rings. Methods Male Wistar rats were divided into sedentary (SD); trained (TR); sedentary diet (SDD) and trained diet (TRD) groups. Run training (RT) was performed in sessions of 60 min, 5 days/week for 12 weeks (70–80% VO2max). Triglycerides, glucose, insulin and nitrite/nitrate concentrations (NOx-) were measured. Concentration-response curves to acetylcholine (ACh) and sodium nitroprusside (SNP) were obtained. Expression of Cu/Zn superoxide dismutase (SOD-1) was assessed by Western blotting. Results High caloric diet increased triglycerides concentration (SDD: 216 ± 25 mg/dl) and exercise training restored to the baseline value (TRD: 89 ± 9 mg/dl). Physical preconditioning significantly reduced insulin levels in both groups (TR: 0.54 ± 0.1 and TRD: 1.24 ± 0.3 ng/ml) as compared to sedentary animals (SD: 0.87 ± 0.1 and SDD: 2.57 ± 0.3 ng/ml). On the other hand, glucose concentration was slightly increased by high caloric diet, and RT did not modify this parameter (SD: 126 ± 6; TR: 140 ± 8; SDD: 156 ± 8 and TRD 153 ± 9 mg/dl). Neither high caloric diet nor RT modified NOx- levels (SD: 27 ± 4; TR: 28 ± 6; SDD: 27 ± 3 and TRD: 30 ± 2 μM). Functional assays showed that high caloric diet impaired the relaxing response to ACh in mesenteric (about 13%), but not in aortic rings. RT improved the relaxing responses to ACh either in aortic (28%, for TR and 16%, to TRD groups) or mesenteric rings (10%, for TR and 17%, to TRD groups) that was accompanied by up-regulation of SOD-1 expression and reduction in triglycerides levels. Conclusion The improvement in endothelial function by physical preconditioning in mesenteric and aortic arteries from high caloric fed-rats was directly related to an increase in NO bioavailability to the smooth muscle mostly due to SOD-1 up regulation.

Older Breast Cancer Survivors: Factors Associated with Self-reported Symptoms of Persistent Lymphedema Over 7 years of Follow-up

Lymphedema of the arm is a common complication of breast cancer with symptoms that can persist over long periods of time. For older women (over 50% of breast cancer cases) it means living with the potential for long-term complications of persistent lymphedema in conjunction with the common diseases and disabilities of aging over survivorship. We identified women > or =65 years diagnosed with primary stage I-IIIA breast cancer. Data were collected over 7 years of follow-up from consenting patients' medical records and telephone interviews. Data collected included self-reported symptoms of persistent lymphedema, breast cancer characteristics, and selected sociodemographic and health-related characteristics. The overall prevalence of symptoms of persistent lymphedema was 36% over 7 years of follow-up. Having stage II or III (OR = 1.77, 95% CI: 1.07-2.93) breast cancer and having a BMI >30 (OR = 3.04, 95% CI: 1.69-5.45) were statistically significantly predictive of symptoms of persistent lymphedema. Women > or =80 years were less likely to report symptoms of persistent lymphedema when compared to younger women (OR = 0.44, 95% CI: 0.18-0.95). Women with symptoms of persistent lymphedema consistently reported worse general mental health and physical function. Symptoms of persistent lymphedema were common in this population of older breast cancer survivors and had a noticeable effect on both physical function and general mental health. Our findings provide evidence of the impact of symptoms of persistent lymphedema on the quality of survivorship of older women. Clinical and research efforts focused on risk factors for symptoms of persistent lymphedema in older breast cancer survivors may lead to preventative and therapeutic measures that help maintain their health and well-being over increasing periods of survivorship.

Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma

BACKGROUND: The objective of this study was to link expression patterns of B-cell-specific Moloney murine leukemia virus integration site 1 (Bmi-1) and p16 to patient outcome (recurrence and survival) in a cohort of 252 patients with oral and oropharyngeal squamous cell cancer (OSCC). METHODS: Expression levels of Bmi-1 and p16 in samples from 252 patients with OSCC were evaluated immunohistochemically using the tissue microarray method. Staining intensity was determined by calculating an intensity reactivity score (IRS). Staining intensity and the localization of expression within tumor cells (nuclear or cytoplasmic) were correlated with overall, disease-specific, and recurrence-free survival. RESULTS: The majority of cancers were localized in the oropharynx (61.1%). In univariate analysis, patients who had OSCC and strong Bmi-1 expression (IRS >10) had worse outcomes compared with patients who had low and moderate Bmi-1 expression (P = .008; hazard ratio [HR], 1.82; 95% confidence interval [CI], 1.167-2.838); this correlation was also observed for atypical cytoplasmic Bmi-1 expression (P = .001; HR, 2.164; 95% CI, 1.389-3.371) and for negative p16 expression (P < .001; HR, 0.292; 95% CI, 0.178-0.477). The combination of both markers, as anticipated, had an even stronger correlation with overall survival (P < .001; HR, 8.485; 95% CI, 4.237-16.994). Multivariate analysis demonstrated significant results for patients with oropharyngeal cancers, but not for patients with oral cavity tumors: Tumor classification (P = .011; HR, 1.838; 95%CI, 1.146-2.947) and the combined marker expression patterns (P < .001; HR, 6.254; 95% CI, 2.869-13.635) were correlated with overall survival, disease-specific survival (tumor classification: P = .002; HR, 2.807; 95% CI, 1.477-5.334; combined markers: P = .002; HR, 5.386; 95% CI, 1.850-15.679), and the combined markers also were correlated with recurrence-free survival (P = .001; HR, 8.943; 95% CI, 2.562-31.220). CONCLUSIONS: Cytoplasmic Bmi-1 expression, an absence of p16 expression, and especially the combination of those 2 predictive markers were correlated negatively with disease-specific and recurrence-free survival in patients with oropharyngeal cancer. Therefore, the current results indicate that these may be applicable as predictive markers in combination with other factors to select patients for more aggressive treatment and follow-up. Cancer 2011;. © 2011 American Cancer Society.

Drug suicide: a sex-equal cause of death in 16 European countries

Background There is a lack of international research on suicide by drug overdose as a preventable suicide method. Sex- and age-specific rates of suicide by drug self-poisoning (ICD-10, X60-64) and the distribution of drug types used in 16 European countries were studied, and compared with other self-poisoning methods (X65-69) and intentional self-injury (X70-84). Methods Data for 2000-04/05 were collected from national statistical offices. Age-adjusted suicide rates, and age and sex distributions, were calculated. Results No pronounced sex differences in drug self-poisoning rates were found, either in the aggregate data (males 1.6 and females 1.5 per 100,000) or within individual countries. Among the 16 countries, the range (from some 0.3 in Portugal to 5.0 in Finland) was wide. 'Other and unspecified drugs' (X64) were recorded most frequently, with a range of 0.2-1.9, and accounted for more than 70% of deaths by drug overdose in France, Luxembourg, Portugal and Spain. Psychotropic drugs (X61) ranked second. The X63 category ('other drugs acting on the autonomic nervous system') was least frequently used. Finland showed low X64 and high X61 figures, Scotland had high levels of X62 ('narcotics and hallucinogens, not elsewhere classified') for both sexes, while England exceeded other countries in category X60. Risk was highest among the middle-aged everywhere except in Switzerland, where the elderly were most at risk. Conclusions Suicide by drug overdose is preventable. Intentional self-poisoning with drugs kills as many males as females. The considerable differences in patterns of self-poisoning found in the various European countries are relevant to national efforts to improve diagnostics of suicide and appropriate specific prevention. The fact that vast majority of drug-overdose suicides came under the category X64 refers to the need of more detailed ICD coding system for overdose suicides is needed to permit better design of suicide-prevention strategies at national level.

Measurement of the cross-section for W boson production in association with b-jets in pp collisions at sqrt(s) = 7 TeV with the ATLAS detector

This paper reports a measurement of the W+b-jets (W+b+X and W+b (b) over bar +X) production cross-section in proton-proton collisions at a centre-of-mass energy of 7 TeV at the LHC. These results are based on data corresponding to an integrated luminosity of 4.6 fb(-1), collected with the ATLAS detector. Cross-sections are presented as a function of jet multiplicity and of the transverse momentum of the leading b-jet for both the muon and electron decay modes of the W boson. The W+b-jets cross-section, corrected for all known detector effects, is quoted in a limited kinematic range. Combining the muon and electron channels, the fiducial cross-section for W+b-jets is measured to be 7.1 +/- 0.5 (stat) +/- 1.4 (syst) pb, consistent with the next-to-leading order QCD prediction, corrected for non-perturbative and double-parton interactions (DPI) contributions, of 4.70 +/- 0.09 (stat) (+0.60)(-0.49) (scale) +/- 0.06 (PDF) +/- 0.16 (non-pert) (+0.52)(-0.38) (DPI) pb.

Response of liquid xenon to Compton electrons down to 1.5 keV

The response of liquid xenon to low-energy electronic recoils is relevant in the search for dark-matter candidates which interact predominantly with atomic electrons in the medium, such as axions or axionlike particles, as opposed to weakly interacting massive particles which are predicted to scatter with atomic nuclei. Recently, liquid-xenon scintillation light has been observed from electronic recoils down to 2.1 keV, but without applied electric fields that are used in most xenon dark-matter searches. Applied electric fields can reduce the scintillation yield by hindering the electron-ion recombination process that produces most of the scintillation photons. We present new results of liquid xenon's scintillation emission in response to electronic recoils as low as 1.5 keV, with and without an applied electric field. At zero field, a reduced scintillation output per unit deposited energy is observed below 10 keV, dropping to nearly 40% of its value at higher energies. With an applied electric field of 450 V/cm, we observe a reduction of the scintillation output to about 75% relative to the value at zero field. We see no significant energy dependence of this value between 1.5 and 7.8 keV. With these results, we estimate the electronic-recoil energy thresholds of ZEPLIN-III, XENON10, XENON100, and XMASS to be 2.8, 2.5, 2.3, and 1.1 keV, respectively, validating their excellent sensitivity to low-energy electronic recoils.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.

OBJECTIVES It is still debated if pre-existing minority drug-resistant HIV-1 variants (MVs) affect the virological outcomes of first-line NNRTI-containing ART. METHODS This Europe-wide case-control study included ART-naive subjects infected with drug-susceptible HIV-1 as revealed by population sequencing, who achieved virological suppression on first-line ART including one NNRTI. Cases experienced virological failure and controls were subjects from the same cohort whose viraemia remained suppressed at a matched time since initiation of ART. Blinded, centralized 454 pyrosequencing with parallel bioinformatic analysis in two laboratories was used to identify MVs in the 1%-25% frequency range. ORs of virological failure according to MV detection were estimated by logistic regression. RESULTS Two hundred and sixty samples (76 cases and 184 controls), mostly subtype B (73.5%), were used for the analysis. Identical MVs were detected in the two laboratories. 31.6% of cases and 16.8% of controls harboured pre-existing MVs. Detection of at least one MV versus no MVs was associated with an increased risk of virological failure (OR = 2.75, 95% CI = 1.35-5.60, P = 0.005); similar associations were observed for at least one MV versus no NRTI MVs (OR = 2.27, 95% CI = 0.76-6.77, P = 0.140) and at least one MV versus no NNRTI MVs (OR = 2.41, 95% CI = 1.12-5.18, P = 0.024). A dose-effect relationship between virological failure and mutational load was found. CONCLUSIONS Pre-existing MVs more than double the risk of virological failure to first-line NNRTI-based ART.

5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.

BACKGROUND In a phase 3, randomised, non-inferiority trial, accelerated partial breast irradiation (APBI) for patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment was compared with whole-breast irradiation. Here, we present 5-year follow-up results. METHODS We did a phase 3, randomised, non-inferiority trial at 16 hospitals and medical centres in seven European countries. 1184 patients with low-risk invasive and ductal carcinoma in situ treated with breast-conserving surgery were centrally randomised to either whole-breast irradiation or APBI using multicatheter brachytherapy. The primary endpoint was local recurrence. Analysis was done according to treatment received. This trial is registered with ClinicalTrials.gov, number NCT00402519. FINDINGS Between April 20, 2004, and July 30, 2009, 551 patients had whole-breast irradiation with tumour-bed boost and 633 patients received APBI using interstitial multicatheter brachytherapy. At 5-year follow-up, nine patients treated with APBI and five patients receiving whole-breast irradiation had a local recurrence; the cumulative incidence of local recurrence was 1·44% (95% CI 0·51-2·38) with APBI and 0·92% (0·12-1·73) with whole-breast irradiation (difference 0·52%, 95% CI -0·72 to 1·75; p=0·42). No grade 4 late side-effects were reported. The 5-year risk of grade 2-3 late side-effects to the skin was 3·2% with APBI versus 5·7% with whole-breast irradiation (p=0·08), and 5-year risk of grade 2-3 subcutaneous tissue late side-effects was 7·6% versus 6·3% (p=0·53). The risk of severe (grade 3) fibrosis at 5 years was 0·2% with whole-breast irradiation and 0% with APBI (p=0·46). INTERPRETATION The difference between treatments was below the relevance margin of 3 percentage points. Therefore, adjuvant APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer is not inferior to adjuvant whole-breast irradiation with respect to 5-year local control, disease-free survival, and overall survival. FUNDING German Cancer Aid.

European multicentre experience with the sutureless Perceval valve: clinical and haemodynamic outcomes up to 5 years in over 700 patients†.

OBJECTIVES This report summarizes the 5-year clinical and haemodynamic data from three prospective, European multicentre trials with the Perceval sutureless aortic valve. METHODS From April 2007 to August 2012, 731 consecutive patients (mean age: 78.5 years; 68.1% females; mean logistic EuroSCORE 10.9%) underwent AVR with the Perceval valve in 25 European centres. Isolated AVR was performed in 498 (68.1%) patients. A minimally invasive approach was performed in 189 (25.9%) cases. The cumulative follow-up was 729 patients-years. RESULTS In isolated AVR, mean cross-clamp and cardiopulmonary bypass times were 30.8 and 50.8 min in full sternotomy, and 37.6 and 64.4 min in the minimally invasive approach, respectively. Early cardiac-related deaths occurred in 1.9%. Overall survival rates at 1 and 5 years were 92.1 and 74.7%, respectively. Major paravalvular leak occurred in 1.4% and 1% at early and late follow-up, respectively. Significant improvement in clinical status was observed postoperatively in the majority of patients. Mean and peak gradients decreased from 42.9 and 74.0 mmHg preoperatively, to 7.8 and 16 mmHg at the 3-year follow-up. LV mass decreased from 254.5 to 177.4 g at 3 years. CONCLUSIONS This European multicentre experience, with the largest cohort of patients with sutureless valves to date, shows excellent clinical and haemodynamic results that remain stable even up to the 5-year follow-up. Even in this elderly patient cohort with 40% octogenarians, both early and late mortality rates were very low. There were no valve migrations, structural valve degeneration or valve thrombosis in the follow-up. The sutureless technique is a promising alternative to biological aortic valve replacement.

INDUCTION OF DNA STRAND BREAKS AND CROSS-LINKS BY THE NEW ANTICANCER AGENT 3,6-DIAZIRIDINYL-2,5-BIS(CARBOETHOXYAMINO) -1,4-BENZOQUINONE

The DNA breakage effect of the anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ, NSC-182986) on bacteriophage PM2 DNA was investigated using agarose gel electrophoresis. AZQ caused both single-stranded and double-stranded breaks after reduction with NaBH(,4), but it was not active in the native state. At 120 (mu)M, it degraded 50% of the closed circular form I DNA into 40% form II DNA (single-stranded break) and 10% form III DNA (double-stranded break). It produced a dose-response breakage between 1 (mu)M and 320 (mu)M. The DNA breakage exhibited a marked pH dependency. At 320 (mu)M, AZQ degraded 80% and 60% of form I DNA at pH 4 and 10 respectively, but none between pH 6 to 8. The DNA breakage at physiologic pH was greatly enhanced when 10 (mu)M cupric sulfate was included in the incubation mixture. The DNA strand scission was inhibited by catalase, glutathione, KI, histidine, Tiron, and DABCO. These results suggest that the DNA breakage may be caused by active oxygen metabolites including hydroxyl free radical. The bifunctional cross-linking activity of reduced AZQ on isolated calf thymus DNA was investigated by ethidium fluorescence assay. The cross-linking activity exhibited a similar pH dependency; highest in acidic and alkaline pH, inactive under neutral conditions. Using the alkaline elution method, we found that AZQ induced DNA single-stranded breaks in Chinese hamster ovary cells treated with 50 (mu)M of AZQ for 2 hr. The single-stranded break frequencies in rad equivalents were 17 with 50 (mu)M and 140 with 100 (mu)M of AZQ. In comparison, DNA cross-links appeared in cells treated with only 1 to 25 (mu)M of AZQ for 2 hr. The cross-linking frequencies in rad equivalents were 39 and 90 for 1 and 5 (mu)M of AZQ, respectively. Both DNA-DNA and DNa-protein cross-links were induced by AZQ in CHO cells as revealed by the proteinas K digestion assay. DNA cross-links increased within the first 4 hr of incubation in drug-free medium and slightly decreased by 12 hr, and most of the cross-links disappeared after cells were allowed to recovered for 24 hr.^ By electrochemical analysis, we found that AZQ was more readily reduced at acidic pH. However, incubation of AZQ with NaBH(,4) at pH 7.8 or 10, but not at 4, produced superoxide anion. The opening of the aziridinyl rings of AZQ at pH 4 was faster in the presence of NaBH(,4) than in its absence; no ring-opening was detected at pH 7.8 regardless of the inclusion of NaBH(,4). . . . (Author's abstract exceeds stipulated maximum length. Discontinued here with permission of author.) UMI ^

Na 1 Nachlass Max Horkheimer, 11 - Korrespondenzen u.a. mit Edward M. David (p. I 6, 1-183)

1 Brief von Fritz Dannenbaum an Max Horkheimer, 26.11.1935; 2 Briefe zwischen F. Darnbacher und Max Horkheimer, 24.01.1936, 22.01.1936; 3 Briefe zwischen dem Dartmouth College Hanover N.H. und Max Horkheimer, 1939-1941. 06.05.1939; 14 Briefe zwischen Edward M. David und Max Horkheimer, 1941-1942; 1 Brief von der Day Cornell University, Ithaca N.Y. an Max Horkheimer, 24.02.1939; 2 Briefe zwischen Margaret Deaner und Max Horkheimer, 01.04.1935, 04.04.1935; 1 Brief von Max Horkheimer an Hanna Deinhard, 05.01.1949; 1 Brief von Deiters an Max Horkheimer, 26.11.1935; 2 Briefe zwischen Laura Demick und Max Horkheimer, 22.12.1941, 29.12.1941; 2 Briefe zwischen Grace Dertz und Max Horkheimer, 18.10.1934, 11.10.1934; 1 Brief von Max Horkheimer an Dekan, 20.06.1940; 1 Brief von Max Dessoir an Max Horkheimer, 29.08.1937; 1 Brief von Max Horkheimer an Deutschland / deutsches Reich Minister für Wissenschaft, Kunst und Volksbildung, Berli, 21.04.1933; 4 Briefe zwischen John Dewey und Max Horkheimer, 1940-1941, 20.02.1941; 1 Brief von Max Horkheimer an Walter Strauss, 20.02.1941; 3 Briefe zwischen Frederic Dewhurst und Max Horkheimer, 1939, 08.02.1939; 5 Briefe zwischen dem Soziograph Jul Diederich und Max Horkheimer, 1934-1938; 1 Brief von Max Horkheimer an Hugo Sinzheimer, 20.10.1934; 15 Briefe zwischen William Dieterle, Charlotte Dieterle und Max Horkheimer, 1940-1944; 1 Brief von der Dillmann-Oberschule Stuttgart an Max Horkheimer, 13.12.1949; 1 Brief vonMax Horkheimer an W. R. Dittmar, 10.02.1938; 2 Briefe zwischen Sofie Doernberg, Paul Doernberg und Margot von Mendelssohn, 1942, 06.04.1942; 4 Briefe zwischen Willy Dörter und Max Horkheimer, 1936-1937, 20.02.1936; 1 Brief von Georg Glaser anMax Horkheimer; 3 Briefe zwischen Hans Venedey und Max Horkheimer, 22.01.1938, 1938; 28 Briefe sowie Zeitungsausschnitte zwischen Juliette Favez und Max Horkheimer, 1934-1938; 1 Brief von Juliette Favez ann karl Dörter, 02.10.1934; 2 Briefe von Max Horkheimer an Hans Klaus Brill, Januar 1938; 3 Briefe zwischen Karl Dörter und Max Horkheimer, 1934-1937, 12.10.1934; 4 Briefe zwischen Andrés Sternheim und Max Horkheimer, 1937, 16.06.1937; 1 Brief von Else Klee an Max Horkheimer, 13.06.1935;

Na 1 Nachlass Max Horkheimer, 55 - Korrespondenzen u.a. mit Julien Wavrinek und Walter Benjamin (p. I 26, 1-130)

2 Briefe zwischen Marga Wadsack und Max Horkheimer, 24.08.1937, 29.08.1937; 1 Brief von Gloria H. Wagner an Max Horkheimer, 27.12.1948; 1 Brief von Herta Wagner an Leo Löwenthal, 05.06.1936; 3 Brief und 1 Beilage zwischen Herta Wagner, 12.03.1936, 1936; 8 Brief zwischen Katja Walch-Lux und Max Horkheimer, 1934-1938; 2 Brief zwischen K. Walcher und Max Horkheimer, 07.08.1936, 04.09.1936 sowie Bemerkungen zum Brief von Max Horkheimer; 2 Briefe zwischen Morris Waldman und Max Horkheimer, 17.04.1940, 11.05.1940; 6 Briefe zwischen Sidney Wallach und Max Horkheimer, 1940; 2 Briefe von Max Horkheimer an Waldman; 2 Briefe von Max Horkheimer an Landau; 1 Brief Max Horkheimer an Warburg; 1 Brief von Hans Wallenberg an Leo Löwenthal, 06.05.1940; 1 Brief von Willard W. Waller an Franz Neumann, 28.04.1941; 2 Briefe und 1 Beilage zwischen Hans Waloschek und Max Horkheimer, 04.08.1938, 31.08.1938; 4 Briefe und 2 Beilagen zwischen Emil J. Walter und Max Horkheimer, 1937, 1938; 5 Briefe und 1 Beilage zwischen Hilde Walter und Max Horkheimer, 1937, 1945; 1 Brief von Rose Walter an Max Horkheimer, 16.11.1938; 2 Briefe zwischen Yu-Chuan Wang und Max Horkheimer, 12.10.1936, 09.12.1936; 1 Brief von Rike Wankmüller-Freyh an Max Horkheimer, 06.07.1949; 1 Brief von Ilse Bach an Heinz Wartenberg, 11.11.1940; 1 Brief von Heinz Wartenberg an Richard Bach, 07.02.1941; 1 Brief von Max Horkheimer an Heinz Wartenberg, 11.03.1941; 1 Brief von Richard Bach an Max Horkheimer; 1 Brief von Franz und Hilde Wasem an Max Horkheimer, 16.02.1949; 5 Briefe zwischen Goodwin Watson und Franz Neumann, 1941; 11 Briefe und Notizen zwischen Julien Wavrinek und Max Horkheimer, 1938-1940; 1 Brief von Max Horkheimer an M. Bruhat; 2 Briefe von Max Horkheimer an Walter Benjamin, 03.05.1940;

Na 1 Nachlass Max Horkheimer, 14 - Korrespondenzen u.a. mit Hugo Fischer und Karl August Wittfogel (p. I 7, 224-429)

1 Brief von Max Horkheimer an Rosel Favez, 03.12.1935; 5 Briefe zwischen Sidney B. Fay von der Bureau of International Search Cambridge, Massachusetts und Max Horkheimer, 1939-1941; 1 Brief von Max Horkheimer an James Feibleman, 02.03.1942; 5 Briefe von Hans Feibelmann an Max Horkheimer, 1936-1937; 2 Briefe zwischen Babette Feigenbaum und Max Horkheimer, 29.04.1941, 05.05.1941; 1 Brief von Arthur Feiler an Max Horkheimer, 15.10.1939; 1 Brief von Max Horkheimer an Adolf Feitler, 03.01.1935; 3 Briefe zwischen Frederick V. Filed von dem American Council Institute of Pacific Relations und Max Horkheimer, 1937, 05.04.1937; 9 Briefe zwischen Thea Field, Lowell Field und Max Horkheimer, 1935-1941; 1 Brief von Max Horkheimer an Finkelstein, 18.09.1941; 7 Briefe zwischen Harry Finkelstein und Max Horkheimer, 1936-1940; 1 Brief von Louis Finkelstein an Robert MacIver, 29.05.1940; 2 Briefe zwischen Louis Finkelstein und Max Horkheimer, 06.06.1940, 04.06.1940; 15 Briefe zwischen Hugo Fischer und Max Horkheimer, 1937-1938; 1 Brief von Hugo Fischer an P. Tillich; 1 Brief von Hugo Fischer an Karl A. Wittfogel, 17.06.1940; 2 Briefe von Max Horkheimer an Ernest Manheim, April 1942; 1 Brief von Alexander Farquharson an Max Horkheimer, 20.01.1940; 3 Briefe zwischen dem Institute of International Education, New York Edgar J. Fisher und Max Horkheimer, Oktober 1938, 18.10.1938; 10 Briefe zwischen Paul Fischer und Max Horkheimer, 1938-1940; 2 Briefe zwischen der Hessian Hills School New York und Max Horkheimer, 21.02.1938, 28.02.1938; 2 Briefe zwischen Dorothy Canfield Fisher und Max Horkheimer, 24.01.1939, 19.01.1939; 1 Brief von Ossip K. Flechtheim an Max Horkheimer, 04.01.1941; 2 Briefe zwischen der University of Minnesota, Minneapolis und Max Horkheimer, 02.08.1945, 15.09.1945; 3 Briefe zwischen Leo Löwenthal und Max Horkheimer, 1943-1945, 17.08.1945; 2 Briefe zwischen der University of Denver, Colorado und Max Horkheimer, 11.05.1943, 28.05.1943; 1 Brief von dem Institute Universitaire De Hautes Etudes Internationales Genf an Max Horkheimer, 25.01.1939; 1 Brief von Hans Kelsen an Max Horkheimer, 30.01.1939; Lebenslauf und 2 Empfehlungsschreiben von Max Fleischmann für Prof. Edwin Borchard; 1 Brief von der Columbia University in the City of New York an Franz Neumann, 17.04.1940; 3 Briefe zwischen Philipp Flesch und Max Horkheimer, 26.03.1940, 1939-1940; 17 Briefe zwischen Babette Fletcher, Theo Fletcher und Max Horkheimer, 1941-1950; 1 Brief von Max Horkheimer an Abraham Flexner, 07.06.1939; 1 Brief von Robert Fließ an Max Horkheimer, 24.10.1938; 1 Brief von der Foreign Policy Association New York an Max Horkheimer, 03.11.1934; 1 Brief von Max Horkheimer an Rudolf Forster, 10.01.1940; 2 Briefe von der Fortune Time & Life Building New York und Max Horkheimer, 1938-1940; 4 Briefe zwischen Siegmund H. Foulkes (Fuchs) und Max Horkheimer, 1936-1937, 31.12.1936; 5 Briefe zwischen Elsie M. Foulstone und Max Horkheimer, 1941; 1 Brief von Mary Fox an Max Horkheimer, 09.12.1938; 5 Briefe zwischen Ernst Fraenkel und Max Horkheimer, 1936-1938; 1 Heiratsanzeige Liesl Frank; 7 Briefe zwischen Philipp Frank und Max Horkheimer, 1937-1939; 6 Briefe zwischen Lothar G. Frank und Max Horkheimer, 1941; 7 Briefe zwischen Felix Frankfurter und Max Horkheimer, 1937-1941; 2 Briefe zwischen Joseph Freeman und Max Horkheimer, 22.11.1944; 1 Brief von der Free Synagogue New York an Max Horkheimer, 14.11.1938; 2 Briefe zwsichen Benjamin Freilichmann und Max Horkheimer, 07.01.1939, 23.01.1939; 2 Briefe zwischen dem Frenkel Travel Service New York und Max Horkheimer, 21.02.1936, 23.02.1936; 2 Briefe zwischen Hugo Freund und Max Horkheimer, 14.11.1938, 18.11.1938; 2 Briefe zwischen Julius A. Jr. Freynick und Max Horkheimer, 11.09.1939, 18.09.1939;

Na 1 Nachlass Max Horkheimer, 686 - Rosenzweig-Test, "Art Project on Fascist Agitator" (p. IX 148.1-2 - IX 149.1-7)

Zum Rosenzweig-Test, 1945; Brown, J.F.: "Memorandum on the Modification of the Rosenzweig Picture Frustration Test". Typoskript, 3 Blatt; Rosenzweig, Saul. "The Picture-Association Method and Its Application in a Study of Reactions to Frustration.", Sonderdruck aus: Journal of Personality, September 1945, S. 3-23; Materialien zum "Art Project on Fascist Agitator" (1945):; 1. "What is a Fascist Agitator?", a) Typoskript, 1 Blatt, b) Typoskript mit handschriftlichen Korrekturen, 2 Blatt; 2. "Some Traits of the Fascist Agitator". Typoskript, 5 Blatt; 3. "Pamphlet", a) Typoskript, 1 Blatt, b) Typoskript, 1 Blatt, c) Typoskript mit dem Titel 'Devices of the Agitator', 1 Blatt; 4. Max Horkheimer: eigenhändige Notizen über den Agitator, 1 Blatt; 5. "Quotes from the Agitator (pages refer to Leo Löwenthals manuscript vol. III)". Typoskript, 7 Blatt; 6. Adressenlisten, 3 Blatt; 7. Materialien zum 'Agitator-Projekt': Photos, Reproduktionen von Zeichnungen und Zeitungsausschnitten;